Sodium cromoglycate is an effective drug in the prophylactic treatment of asthma, especially in children. Its efficacy is ascribed to its ability to inhibit degranulation of mast cells in the respiratory tract.
It is claimed to be as effective as theophylline,5 6 however, a quarter to a third of children appear not to respond to this treatment.7 8 This failure could presumably be due to either a true non-responsiveness to the drug or inadequacy in its delivery to target site.
Using radioimmunoassay to measure sodium cromoglycate in normal volunteers it has been shown that concentrations in the blood are very low after oral ingestion.9 Inhalation of the drug, however, led to much higher concentrations.9 1( We report the results of a prospective study in which the clinical response was compared with concentrations of sodium cromoglycate in serum that were obtained after inhalation of the drug.
Patients and methods
Twenty five children with chronic perennial asthma participated in the study. There The patients recorded the following symptoms in a daily diary on a 0-3 scale of increasing severity: sleep disturbance, cough, wheeze, and impairment of activity. Score 3 was given for each of the following symptoms: severe sleepless night, persistent cough, severe wheezes, and physical disability. Score 0 was given when the patient was asymptomatic. Daily score was determined for each day by the sum of the individual scores given to each symptom (maximum score= 12). Twice daily the patients also measured peak expiratory flow rates (PEFR) at home, using a Mini-Wright peak-flow meter. Patients were assessed clinically at entry to the study and at the end of weeks two, six, and 10. During each assessment patients were examined, PEFR was recorded as described above, and FEV, was measured by a dry spirometer (Vitalograph). Patients were instructed to withhold the use of bronchodilators for at least 24 hours before their clinic visit. On the fourth visit, the patients inhaled one 20 mg spincap of sodium cromoglycate. The technique of inhalation was assessed on a 0-3 scale taking into consideration strength and length of inspiration, motivation of performance, and positioning of patient's head and inhalation device. Venous blood samples for determination of sodium cromoglycate concentrations were drawn at 0, 5, 10, 30, 60, and 120 minutes after inhalation.
Sodium cromoglycate concentration in the serum was determined by the radioimmunoassay method described by Brown et al. 1 Plots of the concentrations versus time were constructed, and area under the curve was calculated by the trapezoidal method.1 '2 Response to treatment was assessed by three parameters: score 0, daily score (DS), and PEFR. The percentage of symptomless days recorded in the diary was calculated for the baseline period and for the eight treatment weeks, and was termed score 0. Mean daily score was calculated from the patients' diaries for both baseline and treatment periods. Mean PEFR was calculated for baseline and treatment periods. For each patient A score 0 and A DS were calculated as the differences between individual score 0, and mean daily score during baseline and treatment periods respectively. A PEFR was the difference between individual mean PEFR at treatment and baseline periods, divided by mean PEFR during baseline period and was expressed in per cent.
Results were expressed as mean (SD). Means were compared by Student's t test, except for the comparison of means of daily score, where the Mann-Whitney test was used.'3 A p value of less than 0 05 was considered significant.
Informed consent was obtained from the parents. The local hospital ethics committee approved the study.
Results Table I shows clinical and pharmacokinetic data of the patients. Treatment with sodium cromoglycate produced no side effects. Mean (SD) score 0 in the baseline period was 19-8 (23-3)% and in the treatment period 59 8 (32-3)% similar to the value obtained by Newth et al. 14 The rise in mean score 0 during treatment is significant (p<0O002). There was no difference in mean score 0 after four or eight weeks of treatment. Mean daily score during the baseline and treatment periods, was 2-64 (1.1) and 0-85 (1-1) respectively (p<0001). Cough and wheeze were the two symptoms which contributed most to the calculated daily score. Mean PEFR during the baseline period was 260 (61)1/minute and during treatment, 307 (76) 1/minute (p<002). FEV,, which was measured only during the clinic visits, was 69 3 (15.5)% on admission to the trial, 78-6 (19.5)% at the end of the baseline period, and 89 5 (18 2)% at the end of the trial.
Serum sodium cromoglycate concentration determined after inhalation of 20 mg of the drug rose rapidly. In 11 patients it reached a peak five minutes after inhalation, in eight patients 10 minutes after inhalation, and in five patients 15 minutes after inhalation. Peak concentrations varied considerably among the patients (table I). Mean peak sodium cromoglycate concentration was 51 [tg/l, and the mean value 120 minutes after inhalation was 13 [tg/l.
The area under the sodium cromoglycate concentration time curve was calculated for each patient. Individual clinical response measured as the parameters A score 0, A DS, and A PEFR were correlated with the pharmacokinetic parameters: area under the curve, peak sodium cromoglycate concentration, and the clinically convenient parameter of sodium cromoglycate concentration 10 minutes after inhalation (SCG 10 minute). Table 2 shows that the correlation between A score 0 as well as A PEFR and all the pharmacokinetic parameters was significant, A DS corre- In order to determine whether the technique of inhalation of sodium cromoglycate affects clinical response to the drug, the pharmacokinetic parameters and clinical response were correlated with the efficiency of the technique of inhalation. Table 3 shows that highly significant correlations were obtained between the area under the curve, peak concentration of sodium cromoglycate, and SCG 10 minutes, and technique of inhalation. The correlation between the area under the curve and technique of inhalation is shown in fig 3. There is also a correlation between clinical response and inhalation technique, but its significance is smaller (table 3) .
Finally, in an attempt to assess the effect of improved delivery of sodium cromoglycate, four patients with low peak sodium cromoglycate concentration were reinstructed in the use of the inhaler. In three patients peak concentrations rose from 19 (10) Ftg/l to 64 (15) [ig/l (p<0-025). In one patient it did not change. 
Discussion
Measurement of sodium cromoglycate concentration enables one to determine the relation between drug concentration and response. As the site of action of this drug is not clinically accessible, measurement of sodium cromoglycate in the blood, apparently reflecting its concentration in the bronchioles, may be informative. Indeed, in normal volunteers it was shown that the concentrations in the blood rise rapidly after inhalation,9 It) whereas after oral ingestion blood concentrations are low,9 thereby explaining the ineffectiveness of oral sodium cromoglycate in asthma. Serum sodium cromoglycate concentrations in our young asthmatic patients rose after inhalation of 20 mg sodium cromoglycate and reached a mean peak of 51 ,ug/l, compared with a mean Concentrations declined promptly to a mean of 13 ig/l at 120 minutes after inhalation, in a similar way to that observed in volunteers.9-1 In contrast, Patel et al found that in asthmatic adults four successive inhalations of 5 mg sodium cromoglycate produced peak concentrations of only 5 ig/l which did not decline for 60 minutes after inhalation. 15 The reasons for this discrepancy are not clear.
A correlation was found between individuals' response and pharmacokinetic parameters. The A score 0 correlated significantly with all three pharmacokinetic parameters. The correlation between A PEFR and these three parameters was also significant, although of lower magnitude. The 6 If technique of inhalation in someway or partly reflects peak inspiratory flow rate (which was not measured in our patients), one could argue that low sodium cromoglycate serum concentrations in some patients were the result rather than the cause of the poorer respiratory performance in the poorly responding patients. Peak inspiratory flow rate, however, falls only in severe obstructive airway disease, which did not occur in our patients. In addition, clinical response to sodium cromoglycate in our study was not related to the initial severity of disease. Two of seven patients with severe disease were poor responders (A score 0 <20%); this is similar to the proportion of poor responders in all the patients (seven out of 25, 28%).
It is not inconceivable, however, that severe airway obstruction may impede delivery of sodium cromoglycate to its target site of action. In such circumstances the use of a bronchodilator before inhalation of this drug or the use of special inhalation devices'7 may be considered and studied.
No side effects of sodium cromoglycate were observed in this study, neither were dose related side effects observed in worldwide experience over many years.3 Because response seems to be related to sodium cromoglycate concentrations in the blood, administration of larger doses than the recommended ones should also be considered.
This study shows that response to sodium cromoglycate is correlated to its concentration in the blood. Most of the non-responding patients have decreased concentrations of the drug, and in some of them this can be improved by additional training in proper use of the inhaler. There may yet be a few patients who do not respond even to apparently therapeutic concentrations of sodium cromoglycate.
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